Verastem (VSTM) closed FY 2025 with fourth quarter revenue of US$17.5 million and a basic EPS loss of US$0.39, alongside a net loss of US$32.9 million. This put hard numbers around a year that also produced trailing twelve month revenue of US$30.9 million and a basic EPS loss of US$3.02. Across the FY 2025 quarters, the company reported revenue of US$0 in Q1, US$2.1 million in Q2, US$11.2 million in Q3 and US$17.5 million in Q4, while quarterly EPS losses ranged between US$0.39 and US$1.35. These figures leave investors focused on how quickly rising sales can start to ease the pressure on margins.

See our full analysis for Verastem.

With the latest numbers on the table, the next step is to set these results against the prevailing stories around Verastem to see which narratives about growth, risk and profitability still hold up and which might need updating.

Revenue climbs from US$0 to US$30.9 million over 12 months

• Across FY 2025, Verastem went from no revenue in Q1 to US$17.5 million in Q4, with trailing twelve month revenue at US$30.9 million and one product approved and launched feeding into those sales.
• Consensus narrative points to AVMAPKI FAKZYNJA CO PACK as the core driver of this revenue. However, the same data show a trailing twelve month net loss of US$209.5 million, so:
  • Analysts referencing this consensus expect revenue to grow strongly, but R&D plus SG&A have already far exceeded the US$11.2 million of net product revenue reported in Q3, which keeps reported losses large.
  • The current cash position of US$137.7 million and a stated runway into the second half of 2026 are tied to this revenue ramp. Any slower prescription build for the launched product would leave that loss profile more exposed.

Stay on top of how these growth numbers feed into the long term story and where bulls and bears currently disagree by checking both sides of the narrative. 🐂 Verastem Bull Case.

Losses stay heavy at over US$200 million on a trailing basis

• On a trailing twelve month basis, Verastem reported a net loss of US$209.5 million and a basic EPS loss of US$3.02, and over the past five years losses have increased at about 27.9% annually with no forecast path to profitability in the next three years.
• Bears focus on this sustained loss profile and the earnings gap, and the recent quarterly figures add weight to that view:
  • Individual quarters in FY 2025 show net losses ranging from US$25.9 million to US$98.5 million, and the third quarter non GAAP adjusted net loss of US$39.4 million compared with US$11.2 million of net product revenue highlights how far operating costs currently run ahead of sales.
  • Forecasts cited in the risk summary explicitly indicate Verastem is expected to remain unprofitable over the next three years, so bears see limited evidence in these numbers that the current spending base will translate into positive earnings within that timeframe.

Skeptics argue that the recent revenue ramp still leaves a large earnings gap, so it is worth seeing how their full thesis lines up with the latest figures. 🐻 Verastem Bear Case.

Valuation signals pull in opposite directions

• At a current share price of US$5.66, the stock is described as trading at a P/S of 16.1x, in line with peers but above the US Biotechs average of 10.9x, while the supplied DCF fair value of US$103.35 and an analyst price target of US$16.38 both sit well above the current price.
• What stands out in the bullish narrative is how strongly those valuation anchors lean on future growth, which sits alongside some clear risks in the same dataset:
  • Forecast revenue growth in the analysis is around 39.1% per year, and bullish analysts referenced in the material assume far higher growth, yet the company is still unprofitable and is expected to stay loss making over the next three years.
  • Major shareholder dilution over the past year is flagged as a key risk. While the gap between US$5.66, the DCF fair value and the US$16.38 target looks large on paper, any further equity raises to fund those growth plans could limit how much of that upside flows through on a per share basis.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Verastem on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between the risks and rewards in these figures, it makes sense to review the data yourself and act promptly to form your own view using the 3 key rewards and 2 important warning signs.

Explore Alternatives

Verastem pairs trailing twelve month revenue of US$30.9 million with a net loss of US$209.5 million and no forecast path to profitability over the next three years.

If you want stocks where earnings and balance sheets do more of the heavy lifting, start comparing ideas in the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.